
Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target
Processa Pharmaceuticals (PCSA) Analyst Ratings
Bulls say
Processa Pharmaceuticals Inc has shown a narrowing of its full-year 2026 net loss per share estimate, decreasing from $0.20 to $0.15, which indicates improved financial performance expectations. The anticipation of positive interim data from the mid-stage trial of its NGC-Cap treatment is seen as a significant potential catalyst for value creation. Additionally, the company has secured a strategic investment and is exploring corporate cryptocurrency treasury strategies, signaling proactive financial management aimed at supporting its growth objectives.
Bears say
Processa Pharmaceuticals is projected to face a substantial net loss of $0.43 per share in 2025, reflective of ongoing financial challenges. The company's growth potential is further constrained by anticipated obstacles such as competition leading to lower pricing and market penetration, as well as possible risks related to partnerships. Additionally, the threat of dilution in the near to medium term raises further concerns regarding the company's financial stability and attractiveness to investors.
This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Processa Pharmaceuticals (PCSA) Analyst Forecast & Price Prediction
Start investing in Processa Pharmaceuticals (PCSA)
Order type
Buy in
Order amount
Est. shares
0 shares